21.82

3.32% -0.75

NewAmsterdam Pharma Company NV (NAMS)

Overview News Price History Financials Why NAMS Down? Discussions Forecast

NewAmsterdam Pharma Company NV stock is currently priced at $21.82, with a 24-hour trading volume of 144.69K. It has seen a -3.32% decreased in the last 24 hours and a -1.31% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $22.53 pivot point. If it approaches the $21.54 support level, significant changes may occur.

Previous Close:

$22.57

Open:

$21.7

24h Volume:

144.69K

Market Cap:

$1.95B

Revenue:

$14.09M

Net Income/Loss:

$-176.94M

P/E Ratio:

-8.187

EPS:

-2.6652

Net Cash Flow:

$-141.24M

1W Performance:

-0.77%

1M Performance:

-1.31%

6M Performance:

+111.43%

1Y Performance:

+0.00%

1D Range:

$21.35

$22.79

52W Range:

$5.6326

$26.35

NewAmsterdam Pharma Company NV Stock (NAMS) Company Profile

Name

NewAmsterdam Pharma Company NV

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

31 35 206 2971

Address

Gooimeer 2-35, Naarden

Employee

Twitter

Next Earnings Date

Latest SEC Filings

NAMS's Discussions on Twitter

NewAmsterdam Pharma Company NV Stock (NAMS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-18-24	Initiated	Guggenheim	Buy
Jan-16-24	Initiated	Piper Sandler	Overweight
Oct-30-23	Initiated	RBC Capital Mkts	Outperform

NewAmsterdam Pharma Company NV Stock (NAMS) Latest News

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

GlobeNewswire Inc.

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

GlobeNewswire Inc.

NewAmsterdam (NAMS) Doses Patient in HeFH Study, Shares Up

Zacks Investment Research

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

GlobeNewswire Inc.

NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

GlobeNewswire Inc.

NewAmsterdam Pharma Company NV Stock (NAMS) Financials Data

NewAmsterdam Pharma Company NV (NAMS) Revenue 2024

NAMS reported a revenue (TTM) of $14.09 million for the quarter ending December 31, 2023.

NewAmsterdam Pharma Company NV (NAMS) Net Income 2024

NAMS net income (TTM) was -$176.94 million for the quarter ending December 31, 2023, a -323.45% decrease year-over-year.

NewAmsterdam Pharma Company NV (NAMS) Cash Flow 2024

NAMS recorded a free cash flow (TTM) of -$141.24 million for the quarter ending December 31, 2023, a -378.20% decrease year-over-year.

NewAmsterdam Pharma Company NV (NAMS) Earnings per Share 2024

NAMS earnings per share (TTM) was -$2.15 for the quarter ending December 31, 2023, a +43.57% growth year-over-year.

NewAmsterdam Pharma Company NV Stock (NAMS) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Kastelein Johannes Jacob Piete	Chief Scientific Officer	Mar 26 '24	Sale	21.50	190,476	4,095,234	0
LANGE LOUIS G	Director	Feb 13 '24	Buy	19.00	5,000	95,000	24,878

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.